Review
doi: 10.1007/s40265-016-0673-1.
Bezlotoxumab: First Global Approval
Affiliations
- PMID: 27905086
- DOI: 10.1007/s40265-016-0673-1
Item in Clipboard
Review
Bezlotoxumab: First Global Approval
Drugs.
2016 Dec.
Abstract
Bezlotoxumab (Zinplava™) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck & Co. In October 2016 it was approved in the USA for reducing the recurrence of C. difficile infection. This article summarizes the milestones in the development of bezlotoxumab leading to this first approval for use in patients receiving antibacterial drug treatment for C. difficile infection who are at high risk for recurrence of C. difficile infection.
Similar articles
-
Bezlotoxumab (Zinplava) for prevention of recurrent Clostridium difficile infection.Med Lett Drugs Ther. 2017 Mar 27;59(1517):49-50. Med Lett Drugs Ther. 2017. Corrected and republished in: JAMA. 2017 Aug 15;318(7):659-660. doi: 10.1001/jama.2017.10092. PMID: 28323808 Corrected and republished. No abstract available.
-
Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.Expert Rev Gastroenterol Hepatol. 2017 Jul;11(7):611-622. doi: 10.1080/17474124.2017.1344551. Epub 2017 Jun 26. Expert Rev Gastroenterol Hepatol. 2017. PMID: 28636484 Review.
-
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?Expert Opin Biol Ther. 2018 Apr;18(4):469-476. doi: 10.1080/14712598.2018.1452908. Epub 2018 Mar 15. Expert Opin Biol Ther. 2018. PMID: 29534621 Review.
-
The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.J Infect Chemother. 2018 Feb;24(2):123-129. doi: 10.1016/j.jiac.2017.10.005. Epub 2017 Oct 31. J Infect Chemother. 2018. PMID: 29097028 Clinical Trial.
-
Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.Pharmacotherapy. 2017 Oct;37(10):1298-1308. doi: 10.1002/phar.1990. Epub 2017 Sep 12. Pharmacotherapy. 2017. PMID: 28730660 Review.
Cited by
-
Monoclonal Antibodies for Bacterial Pathogens: Mechanisms of Action and Engineering Approaches for Enhanced Effector Functions.Biomedicines. 2022 Aug 30;10(9):2126. doi: 10.3390/biomedicines10092126. Biomedicines. 2022. PMID: 36140226 Free PMC article. Review.
-
Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring.J Pers Med. 2020 Sep 25;10(4):147. doi: 10.3390/jpm10040147. J Pers Med. 2020. PMID: 32993004 Free PMC article. Review.
-
Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review.Infect Dis Ther. 2018 Mar;7(1):71-86. doi: 10.1007/s40121-018-0189-y. Epub 2018 Feb 15. Infect Dis Ther. 2018. PMID: 29450831 Free PMC article. Review.
-
A probiotic yeast-based immunotherapy against Clostridioides difficile infection.Sci Transl Med. 2020 Oct 28;12(567):eaax4905. doi: 10.1126/scitranslmed.aax4905. Sci Transl Med. 2020. PMID: 33115949 Free PMC article.
-
Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection.Front Microbiol. 2018 Jun 25;9:1382. doi: 10.3389/fmicb.2018.01382. eCollection 2018. Front Microbiol. 2018. PMID: 29988597 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
